As FDA Tracks 17 Outbreaks, New Rule Would Expose Hidden Food Ingredients

For healthcare and public health audiences, the 17 current foodborne illness investigations—driven by pathogens in leafy greens and jalapeños—reveal a fractured oversight system where unsafe ingredients can slip through unnoticed. The FDA's proposed mandatory GRAS notification rule directly tackles this gap by forcing companies to disclose what they put in our food, potentially slashing outbreak response times and enabling better risk assessment. The directive also highlights the critical need for increased foreign food facility inspections, which the FDA has been unable to complete even half of this year.

On August 10, 2026, the Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., proposed a fundamental shift in U.S. food safety oversight that could reshape how thousands of ingredients enter the food supply. The FDA's plan to convert its voluntary "generally recognized as safe" (GRAS) notification program into a mandatory reporting requirement directly addresses a decades-old regulatory blind spot while simultaneously responding to an alarming wave of foodborne illness outbreaks. The timing is no coincidence: the FDA is currently juggling 17 active investigations into outbreaks tied to Cyclospora in leafy greens and Salmonella in jalapeños, many of which involve imported fresh produce. This dual context — regulatory reform paired with active public health emergencies — gives the proposal both urgency and political momentum.

“

The timing is no coincidence: the FDA is currently juggling 17 active investigations into outbreaks tied to Cyclospora in leafy greens and Salmonella in jalapeños, many of which involve imported fresh produce.

Since 1997, the GRAS process has operated on a voluntary basis, allowing manufacturers to self-determine the safety of new ingredients without any obligation to inform the FDA, much less seek premarket approval. This has created what acting FDA Commissioner Kyle Diamantas called a "decades-old information gap" during the announcement. The proposal does not mandate full premarket approval for every ingredient; rather, it requires companies to notify the FDA of all GRAS determinations, submit the scientific basis for their safety conclusions, and allow the agency an opportunity to intervene if concerns arise. This middle-ground approach aims to balance industry agility with consumer protection, but it also raises the stakes: failure to integrate this data effectively could perpetuate the very risks it seeks to mitigate.

The current outbreak landscape underscores the vulnerabilities. According to the Hearst Get the Facts data team, the 17 active investigations make Cyclospora and Salmonella the most reported pathogens, with jalapeños and iceberg lettuce identified as imported fresh produce vectors. Barbara Kowalcyk, director of the Institute for Food Safety and Nutrition Security at George Washington University, noted that the FDA has inspected less than half of the foreign food facilities it planned to inspect this year, highlighting a critical enforcement gap. In an increasingly globalized food supply, where importers now outnumber domestic producers, the lack of ingredient visibility combined with insufficient foreign inspections creates a perfect storm for outbreaks.

The proposal’s implications extend far beyond immediate compliance. For food manufacturers, the shift to mandatory notification signals a new era of documentation and potential FDA review. While the rule stops short of premarket approval, the mere requirement to submit safety rationales could expose weak justifications and trigger enforcement actions, product reformulations, or even market withdrawals. This could impose new costs and bottlenecks, particularly for smaller companies that lack regulatory affairs expertise, but may also spur innovation in safer ingredient development and build consumer confidence in an era of heightened health awareness.

From a public health perspective, mandatory notification promises to give the FDA — and by extension, epidemiologists and state health departments — a comprehensive chemical and biological map of the food supply. This would drastically speed traceback investigations during outbreaks, as regulators could rapidly identify all products containing a suspect ingredient and assess associated risks. The current system’s opacity has historically hindered such efforts, as the FDA often learns of novel ingredients only after illness clusters emerge. Kennedy’s blunt assessment that "the FDA does not even have a complete picture of what is entering the food supply" resonates with the frustration of public health officials who have long called for mandatory disclosure.